
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 2, 2014

ADVAXIS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

00028489
(Commission File
Number)

02-0563870
(IRS Employer
Identification No.)

**305 College Road East
Princeton, New Jersey**
(Address of principal executive offices)

08540
(Zip Code)

Registrant's telephone number, including area code: **(609) 452-9813**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 2, 2014, the Board of Directors of Advaxis, Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Dr. Samir N. Khleif to serve as a member of the Board, effective as of October 2, 2014. Dr. Khleif has also been appointed to serve as a member of the Research and Development Oversight Committee (“RDOC”) of the Board for the current term, which expires at the next annual meeting of stockholders of the Company.

Dr. Khleif is a principal investigator pursuant to a Non-Clinical Research Agreement that the Company entered into with Georgia Health Sciences University Research Institute (“GHSURI”) on March 1, 2012 and which will remain effective through approximately February 2016. Additionally, Dr. Khleif may act as a principal investigator pursuant to a Master Clinical Trial Agreement, dated February 4, 2014, that the Company entered into with Georgia Regent Research Institute, Inc., a research and educational corporation located at Georgia Regents University.

The Company is currently evaluating the standard annual compensatory arrangement for non-employee directors. Dr. Khleif was granted 26,042 restricted stock units pursuant to the Company’s 2011 Omnibus Incentive Plan, as amended. Such award will vest as to 1,042 shares on October 31, 2014 and thereafter 3,125 restricted stock units will vest on the last day of each of the Company’s next eight fiscal quarters, such that the restricted stock units will vest in full on October 31, 2016, subject to Dr. Khleif’s continued service as a member of the Board through each such vesting date.

Item 7.01 Regulation FD Disclosure

A copy of the Company’s press release regarding Dr. Khleif’s election is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.	Description
99.1	Press Release of Advaxis, Inc. dated October 8, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVAXIS, INC.

By: /s/ Daniel J. O'Connor

Name: Daniel J. O'Connor

Title: Chief Executive Officer and President

Date: October 8, 2014

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Advaxis, Inc. dated October 8, 2014.

ADVAXIS APPOINTS WORLD RENOWNED ONCOLOGIST AND RESEARCH SCIENTIST, DR. SAMIR N. KHELEIF, TO ITS BOARD OF DIRECTORS

PRINCETON, NJ, October 8, 2014 — **Advaxis, Inc.** (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the appointment of world renowned oncologist and research scientist, Dr. Samir N. Khleif, to the Company's Board of Directors. Dr. Khleif has more than 20 years of experience in the medical oncology, tumor immunology and immunotherapy fields.

"We are delighted to welcome Dr. Khleif to Advaxis's Board of Directors," commented Daniel J. O'Connor, President and Chief Executive Officer of Advaxis. "Dr. Khleif's in-depth knowledge of immunotherapy products generally, as well as of our proprietary *Lm-LLO* cancer immunotherapy technology specifically, will be of great value to Advaxis. We look forward to benefiting from his guidance as we work diligently to advance our *Lm-LLO* cancer immunotherapies to create shareholder value."

Dr. Khleif currently serves as the Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center and the Cancer Service Line. Dr. Khleif was formerly Chief of the Cancer Vaccine Section at the National Cancer Institute (NCI), and also served as a Special Assistant to the Commissioner of the Food and Drug Administration (FDA) leading the Critical Path Initiative for oncology. Dr. Khleif is a Georgia Research Alliance Distinguished Cancer Scientist and Clinician and holds a professorship in Medicine, Biochemistry and Molecular Biology, and Graduate Studies at Georgia Regents University.

Dr. Khleif's research program at Georgia Regents University Cancer Center focuses on understanding the mechanisms of cancer-induced immune suppression, and utilizing this knowledge for the development of novel immune therapeutics and vaccines against cancer. His research group designed and performed some of the first cancer vaccine clinical trials targeting specific genetic changes in cancer cells. He led many national efforts and committees on the development of biomarkers and integration of biomarkers in clinical trials, including the AACR-NCI-FDA Cancer Biomarker Collaborative and the ASCO Alternative Clinical Trial Design. Dr. Khleif is the author of many book chapters and scientific articles on tumor immunology and biomarkers process development, and he is the editor for two textbooks on cancer therapeutics, tumor immunology, and cancer vaccines.

Dr. Khleif was inducted into the American Society for Clinical Investigation, received the National Cancer Institute's Director Golden Star Award, the National Institutes of Health Award for Merit, the Commendation Medal of the US Public Health Service, and he was recently appointed to the Institute of Medicine National Cancer Policy Forum.

"Samir's extensive experience with both the science and business of oncology makes him an ideal addition to the Board of Directors of Advaxis," commented James Patton, Chairman of Advaxis. "His guidance and high standards will be invaluable in the advancement of Advaxis's technology to registrational trials and beyond."

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis *Lm-LLO* technology, using bioengineered live attenuated *Listeria monocytogenes* bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registration clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cervical cancer and head and neck cancer.

Advaxis's second *Lm-LLO* immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1/2 clinical study with ADXS-PSA alone and in combination with a PD-1 checkpoint inhibitor. Advaxis is also developing *Lm-LLO* immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc.

For more information please visit www.advaxis.com or connect with us on

- Facebook: <https://www.facebook.com/advaxisinc>
 - Twitter: <https://twitter.com/Advaxis>
 - LinkedIn: <http://www.linkedin.com/company/advaxis-inc>.
 - Google+: <https://plus.google.com/b/115126287957745987074/115126287957745987074/posts>
-

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at <http://www.sec.gov>. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACTS:

Media Contact:

Tiberend Strategic Advisors, Inc.

Amy S. Wheeler

awheeler@tiberend.com

646.362.5750
